Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -14.14
- Piotroski Score 3.00
- Grade Buy
- Symbol (TLSI)
- Company TriSalus Life Sciences, Inc.
- Price $4.30
- Changes Percentage (-3.37%)
- Change -$0.15
- Day Low $4.22
- Day High $4.83
- Year High $10.42
TriSalus Life Sciences, Inc., an immunotherapy company that develops and commercializes immunotherapies for the treatment of liver and pancreatic tumors. The company offers the TriNav Infusion System for hepatic arterial infusion of liver tumors; and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. It also develops SD-101, an investigational immunotherapeutic with pressure-enabled drug delivery technology for hepatocellular carcinoma, intrahepatic cholangiocarcinoma, uveal melanoma with liver metastases, pancreatic ductal adenocarcinoma with liver metastases, colorectal cancer with liver metastases, and primary pancreatic cancers. The company is based in Westminster, Colorado.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/12/2024
- Fiscal Year End N/A
- Average Stock Price Target $11.00
- High Stock Price Target $12.00
- Low Stock Price Target $10.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$2.54
- Trailing P/E Ratio -2.56
- Forward P/E Ratio -2.56
- P/E Growth -2.56
- Net Income $-59,038,000
Income Statement
Quarterly
Annual
Latest News of TLSI
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
TriSalus Life Sciences Inc (TLSI) CEO Buys Shares
Mary Szela, CEO of TriSalus Life Sciences, purchased 14,815 shares, increasing her total holdings to 384,677 shares. The company focuses on innovative cancer treatment methods, with a recent market ca...
By Yahoo! Finance | 2 weeks ago
